NEW YORK ( TheStreet) -- Genzyme Corporation (Nasdaq: GENZ) hit a new 52-week high Thursday as it traded at $75.56 compared with its previous 52-Week high of $75.55. Genzyme is changing hands at $75.56 with 2.2 million shares traded as of 2:26 p.m. ET. Average volume has been 4.6 million shares over the past 30 days. Genzyme has a market cap of $19.6 billion and is part of the health care sector and drugs industry. Shares are up 6% year to date as of the close of trading on Wednesday. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. The company has a P/E ratio of 42.4, below the average drugs industry P/E ratio of 48.1 and above the S&P 500 P/E ratio of 21.5. TheStreet Ratings rates Genzyme as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full Genzyme Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.